Prospective study with HEXA-CAF combination in ovarian carcinoma

G. De Palo, R. Demicheli, Pinuccia Valagussa, M. De Lena, E. Villa, F. Di Re, Silvana Pilotti

Research output: Contribution to journalArticle

Abstract

The value of combination chemotherapy with HEXA-CAF was analyzed in 31 patients with histologically documented epithelial ovarian cancer in advanced stages (minimal or gross disease). No patient had been previously treated with chemotherapy. Peritoneoscopy with diaphragmatic inspection, peritoneal cytology, lymphography, and chest X-ray were routinely used in staging and restaging the patients. Complete (CR) plus partial (PR) responses were obtained in 13/31 fully restaged patients (41.9%). CR was recorded in seven patients (22.5%) and PR in six patients (19.3%). Remission duration was significantly longer in patients who achieved CR (20 months) than in those who attained PR (9.5 months)(P

Original languageEnglish
Pages (from-to)157-161
Number of pages5
JournalCancer Chemotherapy and Pharmacology
Volume5
Issue number3
DOIs
Publication statusPublished - 1981

    Fingerprint

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology

Cite this

De Palo, G., Demicheli, R., Valagussa, P., De Lena, M., Villa, E., Di Re, F., & Pilotti, S. (1981). Prospective study with HEXA-CAF combination in ovarian carcinoma. Cancer Chemotherapy and Pharmacology, 5(3), 157-161. https://doi.org/10.1007/BF00258473